XML 41 R23.htm IDEA: XBRL DOCUMENT
v3.26.1

Basic and Diluted Net Income Per Share | 3 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 29, 2026 | Dec. 28, 2025
Basic and Diluted Net Income Per Share [Abstract] |  |
Basic and Diluted Net Income Per Share | (15) Basic and Diluted Net Income Per Share The Company uses the two-class method to calculate net income per share. No dividends were declared or paid in the thirteen week periods ended March 29, 2026 and March 30, 2025. The following table sets forth the computation of the Company’s basic and diluted net income per share attributable to common stockholders for the thirteen week periods ended March 29, 2026 and March 30, 2025 (in thousands, except share and per share amounts):
|  | Thirteen Weeks Ended |
|  | March 29, |  |  | March 30, |
|  | 2026 |  |  | 2025 |
Numerator for basic income per share: |  |  |  |  |  |  |  |
Net income - basic |  | $ | 5,250 |  |  | $ | 4,812 |
Numerator for diluted income per share |  |  |  |  |  |  |  |
Senior unsecured convertible notes |  |  | (4,882 | ) |  |  | — |
July 2024 Notes derivative liability and interest expense, net of tax |  |  | — |  |  |  | (3,138 | )
Third SAFE |  |  | (49 | ) |  |  | 20 |
Net income - diluted |  | $ | 319 |  |  | $ | 1,694 |
Denominator: |  |  |  |  |  |  |  |
Weighted average shares: |  |  |  |  |  |  |  |
Denominator for basic income per share |  |  | 124,279,055 |  |  |  | 80,209,585 |
Effect of dilutive securities: |  |  |  |  |  |  |  |
Senior unsecured convertible notes |  |  | 16,912,704 |  |  |  |  |
July 2024 Notes derivative liability |  |  | — |  |  |  | 27,364,717 |
Third SAFE |  |  | 2,750,000 |  |  |  | 2,750,000 |
Stock options and RSUs |  |  | 14,705,403 |  |  |  | 1,489,794 |
Warrants |  |  | 166,460 |  |  |  | 487,794 |
Deferred consideration |  |  | 4,973,840 |  |  |  | — |
Denominator for diluted income per share |  |  | 163,787,462 |  |  |  | 112,302,063 |
Net income per share: |  |  |  |  |  |  |  |
Net income - basic |  | $ | 0.04 |  |  | $ | 0.06 |
Net income– diluted |  | $ | 0.00 |  |  | $ | 0.02 |
The Company’s calculation of the weighted average shares outstanding is inclusive of 234,610 warrants with an insignificant exercise price (which assumes that the warrants were outstanding as of the beginning of the period or the date of the grant, whichever is earlier) for the thirteen week period ended March 29, 2026, respectively. The following table presents the potential common shares outstanding that were excluded from the computation of diluted net loss per share of common stock as of the periods presented because including them would have been anti-dilutive:
|  | Thirteen Weeks Ended |
|  | March 29, 2026 |  |  | March 30, 2025 |
Convertible notes |  |  | 65,722,738 |  |  |  | 37,333,318 |
Total potential common shares excluded from diluted net loss per share |  |  | 65,722,738 |  |  |  | 37,333,318 |
| (16) Basic and Diluted Net Loss Per Share The Company uses the two-class method to calculate net loss per share. No dividends were declared or paid in the fiscal years ended December 28, 2025, or December 29, 2024. The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts):
|  | Fiscal Year Ended |
|  | December 28, |  |  | December 29, |
|  | 2025 |  |  | 2024 |
Numerator for basic loss per share: |  |  |  |  |  |
Net loss from continuing operations |  | $ | (44,254 | ) |  | $ | (54,444 | )
Net loss from discontinued operations |  |  | (1,100 | ) |  |  | (2,007 | )
Net loss |  |  | (45,354 | ) |  |  | (56,451 | )
Numerator for diluted loss per share |  |  |  |  |  |  |  |
Impact of September 2024 Notes derivative liability and interest expense, net of tax |  |  | — |  |  |  | (35,886 | )
Net loss |  | $ | (45,354 | ) |  | $ | (92,337 | )
Denominator: |  |  |  |  |  |  |  |
Weighted average shares: |  |  |  |  |  |  |  |
Denominator for basic loss per share |  |  | 87,108,928 |  |  |  | 66,655,837 |
Effect of dilutive securities: |  |  |  |  |  |  |  |
September 2024 Notes derivative liability |  |  | — |  |  |  | 9,137,711 |
Denominator for diluted loss per share |  |  | 87,108,928 |  |  |  | 75,793,548 |
Net loss per share: |  |  |  |  |  |  |  |
Basic: |  |  |  |  |  |  |  |
Continuing operations |  | $ | (0.51 | ) |  | $ | (0.82 | )
Discontinued operations |  |  | (0.01 | ) |  |  | (0.03 | )
Net loss |  | $ | (0.52 | ) |  | $ | (0.85 | )
Diluted |  |  |  |  |  |  |  |
Continuing operations |  | $ | (0.51 | ) |  | $ | (1.19 | )
Discontinued operations |  |  | (0.01 | ) |  |  | (0.03 | )
Net loss |  | $ | (0.52 | ) |  | $ | (1.22 | )
The computation of basic net loss per share attributable to common stockholders is inclusive of warrants with an insignificant exercise price and the minimum number of shares to be issued in connection with the deferred consideration related to the Ambia acquisition. The Company’s calculation of the weighted average shares outstanding with an insignificant exercise price was 234,610 and 3,427,324 warrants (which assumes that the warrants were outstanding as of the beginning of the period or the date of the grant, whichever is earlier) for the fiscal years ended December 28, 2025, and December 29, 2024, respectively. The computation of diluted net loss per share attributable to common stockholders is inclusive of the impact of the Company’s September 2024 Notes (which were dilutive) using the if-converted method for the year ended December 29, 2024. The following table presents the potential common shares outstanding that were excluded from the computation of diluted net loss per share of common stock as of the periods presented because including them would have been anti-dilutive:
|  | Fiscal Year Ended |
|  | December 28, |  |  | December 29, |
|  | 2025 |  |  | 2024 |
Common stock warrants |  |  | 218,847 |  |  |  | 25,434,069 |
Convertible notes |  |  | 82,460,428 |  |  |  | 27,364,717 |
Stock options and RSUs issued and outstanding |  |  | 8,084,064 |  |  |  | 11,979,368 |
Third SAFE Agreement |  |  | 2,750,000 |  |  |  | — |
Deferred consideration shares |  |  | 11,640,506 |  |  |  | — |
Potential common shares excluded from diluted net loss per share |  |  | 105,153,845 |  |  |  | 64,778,154 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-12 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 20 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481468/505-20-05-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration